Zobrazeno 1 - 10
of 1 077
pro vyhledávání: '"Epidermal growth factor receptor mutation"'
Publikováno v:
Annals of Oncology Research and Therapy, Vol 4, Iss 2, Pp 47-50 (2024)
The discovery of targetable mutations in non-small-cell lung cancer (NSCLC) has opened up a plethora of therapeutic options. Epidermal growth factor receptor (EGFR) mutations are found in 10%–20% of NSCLC; however, it is extremely rare in small-cel
Externí odkaz:
https://doaj.org/article/bc09e573b57f4dbcbabf98da831e3a31
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 449-464 (2024)
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC). Similarly, t
Externí odkaz:
https://doaj.org/article/de47c46bff354bd28eaa4efa93d83c7f
Autor:
Hayato Koba, Taro Yoneda, Hiroko Morita, Hideharu Kimura, Yuya Murase, Nanao Terada, Yuichi Tambo, Masafumi Horie, Kazuo Kasahara, Isao Matsumoto, Seiji Yano
Publikováno v:
Thoracic Cancer, Vol 15, Iss 8, Pp 661-666 (2024)
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targe
Externí odkaz:
https://doaj.org/article/af7ce787e5bc4d3ebe70309ad5c2ea41
Autor:
Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Publikováno v:
Thoracic Cancer, Vol 15, Iss 7, Pp 529-537 (2024)
Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutat
Externí odkaz:
https://doaj.org/article/f50013384c9245aabf156b8d88673574
Autor:
Keisuke Tabata, Masaya Aoki, Ryo Miyata, Tadashi Umehara, Aya Harada-Takeda, Go Kamimura, Toshiyuki Nagata, Ryuya Okizono, Hideyuki Terazono, Yasuo Takeda, Takayuki Suetsugu, Kazuhiro Ueda, Masami Sato
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 705-710 (2023)
Although osimertinib is a key drug in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, the safety in hemodialysis patients has not been established. A 76-year-old man was diagnosed with NSCLC
Externí odkaz:
https://doaj.org/article/b5c78c72683442bba4cde407f911b044
Autor:
Tomoyoshi Takenaka, Tokujiro Yano, Koji Yamazaki, Tatsuro Okamoto, Motoharu Hamatake, Shinkichi Takamori, Mikihiro Kohno, Naoko Miura, Mototsugu Shimokawa, Tomoharu Yoshizumi, Kyushu University Lung Surgery Study Group
Publikováno v:
Thoracic Cancer, Vol 14, Iss 18, Pp 1660-1667 (2023)
Abstract Background Long‐term survival can be achieved with radical local therapy in some cases of postoperative recurrence of non‐small cell lung cancer (NSCLC). Here, we evaluated post‐recurrence survival (PRS) after treatment of postoperativ
Externí odkaz:
https://doaj.org/article/98abdd6d760c45e39f49da1c1de77da1
Autor:
Lee ATM, Nagasaka M
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 14, Pp 41-46 (2023)
Alexandria TM Lee,1 Misako Nagasaka1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92868, USA; 2St. Marianna University School of Medicine, Department of Medicine, Kawasaki, JapanCorrespondence: Misako Nag
Externí odkaz:
https://doaj.org/article/24095c4bd07e44088b9aa7d76203dc01
Autor:
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe clinical outcomes of sequential treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs are unclear. Thus
Externí odkaz:
https://doaj.org/article/db4839ec0a994a6298da90412b223b41
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 3, Pp 217-227 (2023)
Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with
Externí odkaz:
https://doaj.org/article/f59c8f22394b42e3a226aba354a41399
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 30-37 (2023)
Abstract Non‐small cell lung cancer (NSCLC) accounts for the majority of all lung cancer diagnoses, and approximately 35% of patients with NSCLC are diagnosed at an early stage (I–IIIA). This study aimed to describe epidermal growth factor recept
Externí odkaz:
https://doaj.org/article/d5e76f8353804ff9a3462c0020166aa0